High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma

被引:14
作者
Bischof, Katharina [1 ,2 ]
Knappskog, Stian [3 ,4 ]
Stefansson, Ingunn [5 ,6 ]
McCormack, Emmet Martin [1 ]
Trovik, Jone [2 ,7 ]
Werner, Henrica Maria Johanna [2 ,7 ]
Woie, Kathrine [2 ]
Gjertsen, Bjorn Tore [1 ,8 ]
Bjorge, Line [1 ,2 ]
机构
[1] Univ Bergen, Dept Clin Sci, Ctr Canc Biomarkers CCBIO, Precis Oncol Res Grp, Bergen, Norway
[2] Haukeland Hosp, Dept Gynecol & Obstet, N-5021 Bergen, Norway
[3] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway
[4] Univ Bergen, Sect Oncol, Dept Clin Sci, Bergen, Norway
[5] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway
[6] Univ Bergen, Sect Pathol, Dept Clin Med, CCBIO, Bergen, Norway
[7] Univ Bergen, Dept Clin Med, Bergen Gynaecol Canc Res Grp, Bergen, Norway
[8] Haukeland Hosp, Dept Internal Med, Haematol Sect, N-5021 Bergen, Norway
关键词
Uterine serous carcinoma; Type II endometrial cancer; p53; isoforms; RT-qPCR; mRNA expression analysis; Biomarker; INDEPENDENT PROGNOSTIC MARKER; CANCER; DELTA-133P53; P53-BETA; THERAPY; LESSONS; VARIANT; P73;
D O I
10.1186/s12885-018-4591-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial carcinoma. Large-scale comprehensive efforts have resulted in an improved molecular understanding of its pathogenesis, and the p53 pathway has been proposed as a key player and is potentially targetable. Here we attempt to further portray the p53 pathway in USC by assessing p53 isoform expression. Methods: We applied quantitative Real-Time PCRs (RT-qPCR) for expression analyses of total p53 mRNA as well as quantitative distinction of p53 beta, p53 gamma, and the total mRNA of amino-terminal truncated Delta 40p53 and Delta 133p53 in a retrospective cohort of 37 patients with USC. TP53 mutation status was assessed by targeted massive parallel sequencing. Findings were correlated with clinical data. Results: The p53 isoform expression landscape in USCs was heterogeneous and dominated by total Delta 133p53, while the distinct p53 beta and p53 gamma variants were found at much lower levels. The isoform expression profiles varied between samples, while their expression was independent of TP53 mutation status. We found high relative p53 gamma expression to be associated with reduced progression-free survival (PFS). Conclusions: This is the first indication that elevated p53 gamma expression is associated with reduced PFS in USC. This singlecenter study may offer some insight in the landscape of p53 isoform expression in USC, but further validation studies are crucial to understand the context-dependent and tissue-specific role of the p53 isoform network in gynecological cancer.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Ovarian Serous Carcinoma: Relationship of p53 and bcl-2 With Tumor Angiogenesis and VEGF Expression
    Crasta, Julian A.
    Mishra, Suniti
    Vallikad, Elizabeth
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2011, 30 (06) : 521 - 526
  • [22] p53 protein expression patterns associated with TP53 mutations in breast carcinoma
    Anderson, Sarah A.
    Bartow, Brooke B.
    Harada, Shuko
    Siegal, Gene P.
    Wei, Shi
    Dal Zotto, Valeria L.
    Huang, Xiao
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 207 (01) : 213 - 222
  • [23] Loss of the p53 transactivation domain results in high amyloid aggregation of the 40p53 isoform in endometrial carcinoma cells
    dos Santos, Nataly Melo
    de Oliveira, Guilherme A. P.
    Rocha, Murilo Ramos
    Pedrote, Murilo M.
    da Silva Ferretti, Giulia Diniz
    Rangel, Luciana Pereira
    Morgado-Diaz, Jose A.
    Silva, Jerson L.
    Pereira Gimba, Etel Rodrigues
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (24) : 9430 - 9439
  • [24] High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma
    Anzola, M
    Saiz, A
    Cuevas, N
    Lopez-Martinez, M
    Martinez de Pancorbo, MA
    Burgos, JJ
    JOURNAL OF VIRAL HEPATITIS, 2004, 11 (06) : 502 - 510
  • [25] Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma
    Liu, XP
    Tsushimi, K
    Tsushimi, M
    Oga, A
    Kawauchi, S
    Furuya, T
    Sasaki, K
    PATHOLOGY INTERNATIONAL, 2001, 51 (06) : 440 - 444
  • [26] Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma
    Abargel, A
    Avinoach, I
    Kravtsov, V
    Boaz, M
    Glezerman, M
    Menczer, J
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (02) : 354 - 359
  • [27] P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
    Said, Rabih
    Hong, David S.
    Warneke, Carla L.
    Lee, J. Jack
    Wheler, Jennifer J.
    Janku, Filip
    Naing, Aung
    Falchook, Gerald S.
    Fu, Siqing
    Piha-Paul, Sarina
    Tsimberidou, Apostolia M.
    Kurzrock, Razelle
    ONCOTARGET, 2013, 4 (05) : 705 - 714
  • [28] Immunohistochemical expression of p53 in breast carcinoma is associated with the intron 1 BglII polymorphism of the p53 gene
    Trejo-Becerril, C
    Sarmiento, RG
    Abad, MM
    Ichaso, N
    Delgado, R
    Cruz, JJ
    Dueñas-González, A
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2000, 452 (02) : 231 - 236
  • [29] Cytoplasmic p53β Isoforms Are Associated with Worse Disease-Free Survival in Breast Cancer
    Reinhardt, Luiza Steffens
    Groen, Kira
    Morten, Brianna C.
    Bourdon, Jean-Christophe
    Avery-Kiejda, Kelly A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (12)
  • [30] Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus
    Kerkhof, Marjon
    Steyerberg, Ewout W.
    Kusters, Johannes G.
    van Dekken, Herman
    van Vuuren, Adriana J.
    Kuipers, Ernst J.
    Siersema, Peter D.
    CANCER BIOMARKERS, 2008, 4 (01) : 1 - 10